Shanghai DeltaHealth Cardiovascular Hospital
Shanghai DeltaHealth Cardiovascular Hospital — Shanghai
Hospital Profile
Shanghai Deda Cardiovascular Hospital (Shanghai Deda Hospital) was founded in 2015/2016 and is the first wholly foreign-owned cardiovascular specialized hospital in the country as well as a high-level privately operated medical institution. In 2024, it was strategically invested in and controlled by Swire Corporation Limited. The hospital is built and managed according to JCI standards and is a general hospital specializing in cardiovascular and oncology disease diagnosis and treatment. It is one of the first international medical tourism pilot units, Shanghai's first private chest pain center (standard version), a designated medical guarantee unit for the China International Import Expo, and a medical support unit for the Beijing Winter Olympics. It once won the Gold Quality Award at the 4th Qingpu District Government Quality Awards.
Medical Milestones
• 2015: Hospital founded. • September 2016: Hospital officially opened; completed the first in-hospital aortic root replacement surgery in the same month; established "Deda Marfan Day." • 2017: Approved to set up a Special Vaccination Clinic. • 2018: Included in high-level social private medical insurance settlement (tertiary settlement level) and became one of the first pilot units for international medical tourism. • 2020: Launched health check-up services. • 2023: Approved as Shanghai's first private Chest Pain Center (standard version) and awarded the Gold Prize of the 4th Government Quality Award in Qingpu District. • 2024: Swire Corporation became the controlling shareholder. • 2025: Officially became the nation's first wholly foreign-owned cardiovascular specialty hospital; the proportion of complex and difficult cardiovascular surgeries exceeded 90%. • 2026: Hosted the 15th Pangu Large Vessel Disease Forum; launched charity medical consultation projects such as "Heart Protection, Health Together."
Key Capabilities & Patient Care
Adhering to the service concept of 'patient-centered care,' we adopt the 'Deda Heart Team' multidisciplinary one-stop diagnosis and treatment model. We implement a 'combination of medical insurance and commercial insurance' model, with medical insurance patients accounting for 90%, and the costs of drugs, consumables, and tests are carried out according to the public tertiary hospital standard prices. Actively assuming social responsibility, we established 'Deda Marfan Day' and the Sun Lizhong Cardiovascular Health Public Welfare Fund, conducting screenings in Xinjiang, Tibet, Yunnan, Jiangxi, and other regions. As of June 2026, we have provided public welfare assistance to a total of 2,360 patients with cardiovascular and pulmonary diseases, and we also provide medical support for large events such as HYROX.
Advanced Technology
Possesses the 'Deda Heart Team,' capable of maturely performing aortic root replacement surgery, multicenter RCT studies on aortic stents, valve repair, structural heart disease interventions, surgical management of heart failure, as well as comprehensive treatments including tumor surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy; certified by the National Medical Device Clinical Trial Institution (GCP). Data Statistics: • Bed Capacity: Approved for 202 beds (38 ICU beds, nearly 19%) (2026) • Number of Departments: - Specialized Departments: Cardiovascular Medicine, Cardiac and Major Vessel Surgery, Medical Imaging and Interventional Therapy, Thoracic Surgery, Oncology - General Departments: Internal Medicine, Surgery, Gynecology, Pediatrics, General Medicine, Otolaryngology, Ophthalmology, Traditional Chinese Medicine, Nutrition, Rehabilitation, Dermatology, Emergency, Special Immunization Outpatient Services, Health Examination Center, etc. • Number of Full-time Physicians: Not disclosed (institution size: 500–999 people) • Number of Multi-site Practitioners / Distinguished Experts: Not disclosed; Professor Sun Lizhong serves as hospital president and GCP principal investigator; the 'Deda Heart Team' offers multidisciplinary one-stop services • Annual Outpatient Volume: Approximately 500,000 outpatient and emergency visits over ten years (2026, cumulative 2016–2026); 90% of patients covered by medical insurance • Surgical Capability: Complex and difficult cardiovascular surgeries account for over 90% in 2025 (2026); maturely performs aortic root replacement, valve repair, structural heart disease interventions, and surgical management of heart failure; first aortic root replacement performed in the opening month of September 2016 • International Certification and Qualifications: Managed according to JCI standards; first batch of international medical tourism pilot units (2018); Shanghai's first private chest pain center standard version (2023); GCP certified; medical support unit for the Beijing Winter Olympics; in 2025, became the first wholly foreign-owned cardiovascular specialty hospital in China • International Services: First batch of international medical tourism pilot units (2018); hybrid 'medical insurance + commercial insurance' model, 90% of patients insured, drug/material/lab costs priced according to public tertiary hospital rates; International Heart Team (Deda model)
International Patient Services
The nation's first wholly foreign-owned cardiovascular specialty hospital, controlled by Swire Group, established as the clinical partner of Columbia University Heart Center in China; supports cross-province medical insurance settlement and direct payment from more than 60 commercial insurance companies; has a special vaccination clinic; internationally renowned experts regularly visit for academic exchanges and lectures.